Biopsychosocial model of irritable bowel syndrome

Journal of Neurogastroenterology and Motility

Volumn 17, Issue 2, 2011, Pages 131-139

  Tanaka, Yukari ^a   Kanazawa, Motoyori ^a   Fukudo, Shin ^a   Drossman, Douglas A ^b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Irritable bowel syndrome; Pathophysiology; Psychology

Indexed keywords

EID: 80054961002     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2011.17.2.131     Document Type: Review

References (85)

1. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II. The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment: a multinational consensus. 2nd ed. McLean, VA: Degnon Associates 2000:1-764.
2. Drossman DA, Ritcher JE, Talley NJ, et al. Functional gastrointestinal disorders. Boston: Little Brouwn 1994:1-174.
3. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001;358:1504-1508.
4. Gwee KA, Bak YT, Ghoshal UC, et al. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1189-1205.
5. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999-1007.
6. Longstreth GF, Drossman DA. Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol 2005;3:397-400.
7. Ananthakrishnan AN, McGinley EL, Saeian K. Length of office visits for gastrointestinal disease: impact of physician specialty. Am J Gastroenterol 2010;105:1719-1725.
8. Drossman DA. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom Med 1998;60:258-267.
9. Halpert A, Drossman D. Biopsychosocial issues in irritable bowel syndrome. J Clin Gastroenterol 2005;39:665-669.
10. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977;196:129-136.
11. Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry 1980;137:535-544.
12. Drossman DA. The functional gastrointestinal disorders and the Rome III process. In: Drossman DA, Corazziari E, Delvaux M, Spiller R, Talley NJ, Thompson WG, Whitehead WE, et al, eds. Rome III: the functional gastrointestinal disorders. 3rd ed. McLean, VA: Degnon Associates 2006:1-30.
13. Locke GR 3rd, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ 3rd. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000;75:907-912.
14. Morris-Yates A, Talley NJ, Boyce PM, Nandurkar S, Andrews G. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998;93:1311-1317.
15. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001;121:799-804.
16. Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhea predominant irritable bowel syndrome in women. Gut 2004;53:1452-1458.
17. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52:91-93.
18. Levy RL, Whitehead WE, Walker LS, et al. Increased somatic complaints and health-care utilization in children: effects of parent IBS status and parent response to gastrointestinal symptoms. Am J Gastroenterol 2004;99:2442-2451.
19. Levy RL, Whitehead WE, Von Korff MR, Feld AD. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000;95:451-456.
20. Kanazawa M, Endo Y, Whitehead WE, Kano M, Hongo M, Fukudo S. Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. Dig Dis Sci 2004;49:1046-1053.
21. Levy RL, Whitehead WE, Walker LS, et al. Increased somatic complaints and health-care utilization in children: effects of parent IBS status and parent response to gastrointestinal symptoms. Am J Gastroenterol 2004;99:2442-2451.
22. Walker LS, Williams SE, Smith CA, Garber J, Van Slyke DA, Lipani TA. Parent attention versus distraction: impact on symptom complaints by children with and without chronic functional abdominal pain. Pain 2006;122:43-52.
23. Sarason IG, Johnson JH, Siegel JM. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychol 1978;46:932-946.
24. Kirmayer LJ, Young A. Culture and somatization: clinical, epidemiological, and ethnographic perspectives. Psychosom Med 1998;60: 420-430.
25. Drossman DA, Li Z, Leserman J, Toomey TC, Hu YJ. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology 1996;110:999-1007.
26. Drossman DA, Talley NJ, Leserman J, Olden KW, Barreiro MA. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med 1995;123:782-794.
27. Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990;113:828-833.
28. Drossman DA, Creed FH, Olden KW, Svedlund J, Toner BB, Whitehead WE. Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999;45(suppl 2):II25-II30.
29. Drossman DA, Chang L. Psychosocial factors in the care of patients with GI disorders. In: Yamada T, ed. Textbook of gastroenterology. Philadelphia: Lippincott-Raven 2003:636-654.
30. Drossman DA, Ringel Y, Vogt BA, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 2003;124:754-761.
31. Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997;112:2120-2137.
32. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992;33:825-830.
33. Olden KW, Drossman DA. Psychologic and psychiatric aspects of gastrointestinal disease. Med Clin North Am 2000;84:1313-1327.
34. Walker EA, Roy-Byrne PP, Katon WJ, Li L, Amos D, Jiranek G. Psychiatric illness and irritable bowel syndrome: a comparison with inflammatory bowel disease. Am J Psychiatry 1990;147:1656-1661.
35. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990;98(5 Pt 1):1187-1192.
36. Bennett EJ, Piesse C, Palmer K, Badcock CA, Tennant CC, Kellow JE. Functional gastrointestinal disorders: psychological, social, and somatic features. Gut 1998;42:414-420.
37. Lackner JM, Gurtman MB. Pain catastrophizing and interpersonal problems: a circumplex analysis of the communal coping model. Pain 2004;110:597-604.
38. Cano A, Leonard MT, Franz A. The significant other version of the Pain Catastrophizing Scale (PCS-S): preliminary validation. Pain 2005;119:26-37.
39. Lackner JM, Quigley BM, Blanchard EB. Depression and abdominal pain in IBS patients: the mediating role of catastrophizing. Psychosom Med 2004;66:435-441.
40. Ringel Y, Drossman DA, Leserman JL, et al. Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology 2008;134:396-404.
41. Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry 2001;49:1023-1039.
42. Creed F. The relationship between psychosocial parameters and outcome in irritable bowel syndrome. Am J Med 1999;107:74S-80S.
43. Porter M, Gorman D. Approaches to somatisation. BMJ 1989; 298:1332-1333.
44. Fukudo S, Nomura T, Muranaka M, Taguchi F. Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome. A preliminary study. J Clin Gastroenterol 1993;17:133-141.
45. Ness TJ, Metcalf AM, Gebhart GF. A psychophysiological study in humans using phasic colonic distension as a noxious visceral stimulus. Pain 1990;43:377-386.
46. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651-1659.
47. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
48. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26-37.
49. Paquette V, Lévesque J, Mensour B, et al. " Change the mind and you change the brain" : effects of cognitive-behavioral therapy on the neural correlates of spider phobia. Neuroimage 2003;18:401-409.
50. Tougas G. The autonomic nervous system in functional bowel disorders. Gut 2000;47(suppl 4):iv78-iv80.
51. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Psychoneuroimmunology and psychosomatic medicine: back to the future. Psychosom Med 2002;64:15-28.
52. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999;45(suppl 2):II1-II5.
53. Tucker DM, Luu P, Pribram KH. Social and emotional selfregulation. Ann N Y Acad Sci 1995;769:213-239.
54. Elsenbruch S, Rosenberger C, Enck P, Forsting M, Schedlowski M, Gizewski ER. Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 2010;59:489-495.
55. Elsenbruch S, Rosenberger C, Bingel U, Forsting M, Schedlowski M, Gizewski ER. Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology 2010;139:1310-1319.
56. Kanba S, Richelson E. Histamine H1 receptors in human brain labelled with [3H]doxepin. Brain Res 1984;304:1-7.
57. Watanabe S, Hattori T, Kanazawa M, Kano M, Fukudo S. Role of histaminergic neurons in hypnotic modulation of brain processing of visceral perception. Neurogastroenterol Motil 2007;19:831-838.
58. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998;42:845-849.
59. Petrusz P, Merchenthaler I. The corticotropin-releasing factor system. In: Nemeroff CB, ed. Neuroendocrinology. Boca Raton, Florida: CRC Press 1992:129-183.
60. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996;347:150-153.
61. Marshall JK, Thabane M, Garg AX, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010;59:605-611.
62. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132: 913-920.
63. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002;51:410-413.
64. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:349-357.
65. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999;44: 400-406.
66. Drossman DA. Mind over matter in the postinfective irritable bowel. Gut 1999;44:306-307.
67. Lazarus RS, Folkman S. Stress, appraisal and coping. New York: Springer-Verlag 1984:117-139.
68. Berkman LF. Assessing the physical health effects of social networks and social support. Annu Rev Public Health 1984;5:413-432.
69. Jones MP, Wessinger S, Crowell MD. Coping strategies and interpersonal support in patients with irritable bowel syndrome and inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:474-481.
70. Camilleri M, Bueno L, de Ponti F, Fioramonti J, Lydiard RB, Tack J. Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology 2006;130:1421-1434.
71. Drossman DA. Psychosocial sound bites: exercises in the patient-doctor relationship. Am J Gastroenterol 1997;92:1418-1423.
72. Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 2006;130: 1447-1458.
73. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005;54:601-607.
74. Creed F. How do SSRIs help patients with irritable bowel syndrome? Gut 2006;55:1065-1067.
75. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-747.
76. Friedrich M, Grady SE, Wall GC. Effects of antidepressants in patients withirritable bowel syndrome and comorbid depression. Clin Ther 2010;32:1221-1233.
77. Yin J, Wang W, Winston JH, Zhang R, Chen JD. Ameliorating effects of mirtazapine on visceral hypersensitivity in rats with neonatal colon sensitivity. Neurogastroenterol Motil 2010;22:1022-1028, e267.
78. Rogers M, Cerda JJ. The narcotic bowel syndrome. J Clin Gastroenterol 1989;11:132-135.
79. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005;17:332-340.
80. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008;336:999-1003.
81. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31.
82. Toner BB. Cognitive-behavioral treatment of functional somatic syndromes: integrating gender issues. Cogn Behav Pract 1994;1:157-178.
83. Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 2006;130: 1447-1458.
84. Hattori T, Watanabe S, Kano M, Kanazawa M, Fukudo S. Differntial responding of autonomic function to histamine H1 antagonism in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:1284-1291, e335.
85. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol 2004;72:1100-1113.